| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DGX | Common Stock | Options Exercise | $56,812 | +1,010 | +4.2% | $56.25 | 24,943 | 01 Jul 2022 | Direct | F1 |
| transaction | DGX | Common Stock | Options Exercise | $58,098 | +990 | +4% | $58.68 | 25,933 | 01 Jul 2022 | Direct | F1 |
| transaction | DGX | Common Stock | Sale | $266,940 | -2,000 | -7.7% | $133.47 | 23,933 | 01 Jul 2022 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DGX | Stock Options (Right to Buy) | Options Exercise | $56,812 | -1,010 | -87% | $56.25 | 149 | 01 Jul 2022 | Common Stock | 1,010 | $56.25 | Direct | F1 |
| transaction | DGX | Stock Options (Right to Buy) | Options Exercise | $58,098 | -990 | -100% | $58.68 | 0 | 01 Jul 2022 | Common Stock | 990 | $58.68 | Direct | F1 |
| transaction | DGX | Phantom Stock Units | Award | $41,498 | +308 | +2.6% | $134.74 | 12,355 | 01 Jul 2022 | Common Stock | 308 | $0.000000 | Direct | F2, F3 |
| Id | Content |
|---|---|
| F1 | This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on June 1, 2022. |
| F2 | Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. |
| F3 | Total number of phantom stock units accrued as of the transaction date in the reporting person's deferred compensation account includes phantom stock units credited as a result of dividend reinvestment transactions exempt from reporting pursuant to Rule 16a-11. |